Study Evaluating Vabicaserin in Subjects With Schizophrenia
Public ClinicalTrials.gov record NCT00563706. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Risperidone-Referenced, Parallel-Group, Adaptive-Design Study of the Efficacy, Safety, and Tolerability of Vabicaserin (SCA-136) in Subjects With Acute Exacerbations of Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary purpose of this protocol is to establish the efficacy, safety, and tolerability of vabicaserin (SCA-136) using a once a day capsule in subjects with acute exacerbations of schizophrenia.
Study identification
- NCT ID
- NCT00563706
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 199 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- Male
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 2007 (Type not available)
- Primary completion
- Jun 2008 (Actual)
- Completion
- Jun 2008 (Actual)
- Last update posted
- Mar 20, 2014
2007 – 2008
United States locations
- U.S. sites
- 32
- U.S. states
- 15
- U.S. cities
- 30
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Little Rock | Arkansas | 72201 | — |
| Pfizer Investigational Site | Cerritos | California | 90703 | — |
| Pfizer Investigational Site | Escondido | California | 92025 | — |
| Pfizer Investigational Site | Garden Grove | California | 92845 | — |
| Pfizer Investigational Site | Glendale | California | 91206 | — |
| Pfizer Investigational Site | San Diego | California | 92103 | — |
| Pfizer Investigational Site | San Diego | California | 92123 | — |
| Pfizer Investigational Site | Torrance | California | 90502 | — |
| Pfizer Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Pfizer Investigational Site | Aventura | Florida | 33180 | — |
| Pfizer Investigational Site | Hollywood | Florida | 33021 | — |
| Pfizer Investigational Site | Kissimmee | Florida | 34741 | — |
| Pfizer Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Pfizer Investigational Site | Indianapolis | Indiana | 46222 | — |
| Pfizer Investigational Site | Lake Charles | Louisiana | 70601 | — |
| Pfizer Investigational Site | Baltimore | Maryland | 21202 | — |
| Pfizer Investigational Site | Rockville | Maryland | 20850 | — |
| Pfizer Investigational Site | Hamilton | New Jersey | 08619 | — |
| Pfizer Investigational Site | Willingboro | New Jersey | 08046 | — |
| Pfizer Investigational Site | Cedarhurst | New York | 11516 | — |
| Pfizer Investigational Site | Holliswood | New York | 11423 | — |
| Pfizer Investigational Site | New York | New York | 10032 | — |
| Pfizer Investigational Site | Butner | North Carolina | 27509 | — |
| Pfizer Investigational Site | Oklahoma City | Oklahoma | 73103 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19131 | — |
| Pfizer Investigational Site | Austin | Texas | 78754 | — |
| Pfizer Investigational Site | Austin | Texas | 78756 | — |
| Pfizer Investigational Site | Bellaire | Texas | 77008 | — |
| Pfizer Investigational Site | DeSoto | Texas | 75115 | — |
| Pfizer Investigational Site | Houston | Texas | 77008 | — |
| Pfizer Investigational Site | Arlington | Virginia | 22201 | — |
| Pfizer Investigational Site | Portsmouth | Virginia | 23707 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00563706, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00563706 live on ClinicalTrials.gov.